Fluorouracilum
Esophageal Squamous Cell Carcinoma
Explore 64 assets in Esophageal Squamous Cell Carcinoma →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
AstraZeneca
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06535607CT.gov Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05945823CT.gov Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04949256CT.gov Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) | — | Active Not Recruiting | — | — | — |
NCT04210115CT.gov Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | — | Active Not Recruiting | — | — | — |
NCT02658214CT.gov Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Esophageal Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fluorouracilum (this asset) | AstraZeneca | P3 | BB · 66 |
| Levofolinic Acid | Taiho Oncology, Inc. | P3 | BB |
| Irinotecan | Taiho Oncology, Inc. | P2 | BB |
| Oxaliplatin | Taiho Oncology, Inc. | P3 | B |
| Cetuximab | Hummingbird Bioscience | P2 | B |
| Pembrolizumab | GV20 Therapeutics | P3 | B |
| Cis-Diamminedichloroplatinum Ii | AstraZeneca | P3 | B |
| Capecitabine | Chongqing University Cancer Hospital | P2 | B |
| Lenvatinib | Merck Sharp & Dohme LLC | P3 | B |
+42 more in the Esophageal Squamous Cell Carcinoma cohort
Other indications for Fluorouracilum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 77 |
| Rectal Cancer | — | P3 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fluorouracilum in Esophageal Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fluorouracilum-esophageal-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →